Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post hoc comparison of 177Lu-PSMA-617 versus SBRT in oligometastatic recurrent prostate cancer
NL-OMON57993Not yet recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Jan 2026
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Small Molecules
- Countries
- 1
01
Overview
Open-label trial of lutetium lu 177 vipivotide tetraxetan in prostate cancer (PCa) (2 arms), sponsored by Radboud University Medical Center. Primary endpoint: Androgen deprivation therapy-free survival. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
lutetium lu 177 vipivotide tetraxetan
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON57993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON57993.